✓ Credit card payment restored — secure checkout via Privacy Shield

Aprecap

Aprecap (Aprepitant 125/80 mg) — Cipla NK1 receptor antagonist antiemetic for prevention of acute and delayed chemotherapy-induced nausea/vomiting.

Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience  · Last reviewed: May 2026

Encrypted checkout
Crypto pays 10% less
Discreet worldwide delivery
1,400+ customers · 50+ countries

This product is currently out of stock and unavailable.

Quick Answer

Aprecap — Aprepitant 125 mg/80 mg (Cipla Inc). NK1 receptor antagonist antiemetic for prevention of acute and delayed nausea/vomiting from highly and moderately emetogenic chemotherapy (cisplatin, AC, MEC). Used in combination with 5-HT3 antagonist + dexamethasone.

What you get with MedsBase:

  • WHO-GMP certified manufacturer
  • Discreet plain-envelope packaging
  • Worldwide shipping
  • Rated by 1,400+ customers (read reviews)

📦 Reshipment Assurance: if your order has not arrived 20 business days after dispatch, we reship it at no extra cost. Read the policy.

Why order from MedsBase

Aprecap ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.

⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.

CYP3A4 interactions
Aprepitant is a moderate CYP3A4 inhibitor. Significant interactions with dexamethasone (raises levels — dose-reduce dexamethasone 50%), warfarin (transient INR fall), oral contraceptives (efficacy reduced — use additional non-hormonal method during therapy and for 1 month after).

Frequently Asked Questions

When is this used?

NK1 receptor antagonist antiemetic for prevention of acute and delayed nausea/vomiting from highly and moderately emetogenic chemotherapy (cisplatin, AC, MEC). Used in combination with 5-HT3 antagonist + dexamethasone.

Side effects?

Class-specific — see safety boxes above. Most supportive cancer medications are well-tolerated when used per protocol but require specialist supervision.

Drug interactions?

Always disclose all medications. Cancer supportive therapy interacts with multiple cytotoxics, chemo regimens, and concomitant medications.

Pregnancy?

Variable by molecule. Consult oncology for pregnancy planning during cancer therapy.

Monitoring?

Specialist-determined — typically FBC, electrolytes, renal/liver function, cardiac monitoring as relevant.

What if I miss a dose?

Take when you remember; do not double up. Discuss with oncology team if multiple doses missed.

When is treatment finished?

Determined by clinical response, planned regimen length, and patient tolerance.

Storage?

Per package insert — typically below 25-30°C, away from light and moisture. Pregnant household members should not handle broken tablets/capsules.

Cost?

Generic Indian biosimilars and chemical equivalents are dramatically less expensive than originator products with documented bioequivalence and clinical equivalence.

Vaccines?

Coordinate with oncology — live vaccines may be contraindicated during cancer therapy.

Other Cancer & Supportive Medications

  • Xeloda — capecitabine 500 mg — oral 5-FU prodrug for breast/colorectal/gastric cancers
  • Altraz — anastrozole 1 mg — aromatase inhibitor for post-menopausal breast cancer
  • Xbira — abiraterone 250 mg — CYP17 inhibitor for metastatic prostate cancer
  • Zoldria — zoledronic acid IV — for bone metastases and hypercalcaemia
  • Actorise — darbepoetin alfa — for chemotherapy-induced anaemia
Medical Disclaimer: Cancer therapy is highly individualised. Specific drug, dose, schedule, monitoring, and supportive care must be determined by a qualified oncologist or haematologist based on tumour biology, staging, comorbidities, and goals of care. This information is educational; it does not substitute for professional medical advice.

More options in Anti Cancer Medication

Ranked by recent MedsBase order volume — what other customers in this category are picking.

Strength

125 mg

Quantity

3 Capsule/s, 6 Capsule/s, 9 Capsule/s

Pharma Form

Tablet/s

Manufacturer

Glenmark Pharmaceuticals

Treatment

Nausea and vomiting due to chemotherapy

Generic Brand

Aprepitant

Reviews

There are no reviews yet

Add a review
Aprecap Aprecap
Rating*
0/5
* Rating is required
* Answer is required
Your review
* Review is required
Name
* Name is required
Add photos or video to your review

Q & A

Ask a question
Aprecap Aprecap
Your question
* Question is required
Name
* Name is required
There are no questions yet